Methods of viral mimicry for the treatment of BC
| Drug categories | Drug names | Methods for assessing the effects of drugs [Reference] |
|---|---|---|
| DNA methyltransferase inhibitors* | 5-aza-2-deoxycytidine, guadecitabine | Human BC stem cells [27] |
| Guadecitabine | Experiments on mice, clinical trials [28, 29] | |
| Decitabine | Human BC cell line and experiments on mice [31] | |
| CC-486 + durvalumab (immune checkpoint inhibitor) | Clinical trials (phase II) [32] | |
| Bifunctional DNA methyltransferase and histone deacetylase inhibitors* | J208 | TNBC cell line [33] |
| Histone deacetylase inhibitors* | Depsipeptide, trichostatin A | BC cell line [34, 35] |
| Didemnin B (cyclic depsipeptide) | Clinical trials (phase II) [36] | |
| 15a | Human BC cell line [37] | |
| 12a-c | TNBC cell line [38] | |
| Vorinostat | Basal-like BC cell line [39] | |
| Clinical trials (phase IB) [40] | ||
| Entinostat | Clinical trials (phase II [41], phase III [42]) | |
| Panobinostat | TNBC cell line [49] | |
| Histone methyltransferase inhibitors* | EPZ004777 | Antiestrogen-resistant BC cells [43] |
| EPZ-5676 | TNBC stem cells [44] | |
| Tazemetostat, GSK126, U3i | TNBC cell line [45] |